109.78 +0.37 (0.34%)
After hours: 6:59PM EST
|Bid||109.41 x 500|
|Ask||110.00 x 200|
|Day's Range||107.68 - 109.64|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||25.64|
|Earnings Date||Jan 24, 2018 - Jan 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||124.83|
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Presentations on potentially game-changing gene therapies were front and center at this year's American Society of Hematology conference.
Juno is now the cheapest CAR-T player, an analyst said Wednesday as he downgraded rival Bluebird on a lack of catalysts until the spring.
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
Shares of Intercept Pharmaceuticals (ICPT) are higher on Wednesday, following a bullish note from Deutsche Bank, which also initiated coverage on Celgene (CELG) and Regeneron (REGN). Analyst Navin Jacob ...
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
The Cambridge, Mass.-based firm's presentations at the American Society of Hematology's annual meeting sent its stock soaring on Monday.
Data from LentiGlobin in sickle cell disease gives us confidence the mfr improvements could lead to increased efficacy, and we think a second SCD pt has achieved a functional cure. Elsewhere, Barclay's Gena Wang reiterated an Outperform rating and $162 price target on bluebird: Despite increasing competition with multiple BCMA data presented at the ASH over the weekend, BLUE’s bb2121 continued to show potentially best-in-class BCMA CAR-T asset in R/R multiple myeloma. Its superior safety and efficacy profile makes bb2121 feasible to move to earlier lines of therapy C a significantly larger market opportunity for CAR T therapy.
Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer. Kyprolis when used with two standard of care drugs, dexamethasone and Celgene Corp's Revlimid, reduced the risk of death by 21 percent and extended survival by 7.9 months, compared with patients treated with the two drugs alone, the company said. The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib, in multiple myeloma patients whose cancer had relapsed following prior treatment or did not respond to treatment.
Several biotechnology stocks vaulted into double-digit gains after reporting clinical data on blood-disorder medications.
The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited ...
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Amid the proceedings at the American Society of Hematology's, or ASH, 59th annual meeting, Morgan Stanley highlighted what it views as the biggest potential positive for Celgene Corporation (NASDAQ: CELG ...
bluebird bio Inc (NASDAQ: BLUE ) reported compelling data over the weekend at the American Society of Hematology that some experts described as "unheard of." The Analyst Cantor Fitzgerald's ...
The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics